Preston Noon

Preston is clinically trained as a Doctor of Pharmacy, in addition to earning an MBA from the University of Connecticut. The combined technical and business acumen provides a strong foundation to support venture capital life sciences investments across all stages of drug development, as demonstrated by the successful investments he led across the Agent Capital portfolio. 

​

Preston is closely tied into the venture and entrepreneur communities on the East coast, primarily in Cambridge/Boston area and the greater NYC region. He is an active mentor to colleagues and graduate university students aspiring to become industry leaders in biopharmaceuticals and/or venture capital.

Preston is General Partner and Co-Founder of Agent Capital, a healthcare venture capital firm investing in life sciences. Since 2017, the firm has made 14 investments resulting in 4 IPO exits and over $25B in business development partnership milestones for its portfolio companies. Preston supports all Agent Capital fund activities, including leading new investments, fundraising, portfolio management, and maintaining back-office functions (audit, finance, LP reporting, etc.).

​

Prior to Agent Capital, Preston worked in the pharmaceutical industry for Bristol-Myers Squib, Bayer, and Baxalta (a NYSE listed spinout from Baxter Healthcare). At Bayer, Preston was a post-doctoral Associate for the U.S. Business Development and Licensing group at Bayer, where he worked on in-licensing assets, acquisitions and asset divestitures. Prior to Bayer, Preston was a global medical affairs analyst at Bristol-Myers Squibb. He began his career in the pharmaceutical industry working at Bristol-Myers Squibb to support clinical trial operations, specifically to monitor and improve enrollment timelines for next generation immuno-oncology assets including ipilimumab and nivolumab, which are now approved.

Preston is serving his fellowship at Agent Capital in Boston, Massachusetts under the mentorship of Geeta Vemuri, Founding Managing Partner. Preston is a member of the Kauffman Fellowship Class 23